HSP90 as a novel molecular target in non-small-cell lung cancer
Khashayar Esfahani, Victor Cohen Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, QC, Canada Abstract: Lung cancer remains the most lethal cancer, with over 160,000 annual deaths in the USA alone. Over the past decade, the discovery of driver mutations has changed the land...
Guardado en:
Autores principales: | Esfahani K, Cohen V |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c825e459e0d84d2aafce3734f4eeb073 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Inhibitors of the <i>Plasmodium falciparum</i> Hsp90 towards Selective Antimalarial Drug Design: The Past, Present and Future
por: Melissa Louise Stofberg, et al.
Publicado: (2021) -
HSP90 and HSP70 Families in Lateolabrax maculatus: Genome-Wide Identification, Molecular Characterization, and Expression Profiles in Response to Various Environmental Stressors
por: Yalong Sun, et al.
Publicado: (2021) -
Hybrid Nanoparticles Modified by Hyaluronic Acid Loading an HSP90 Inhibitor as a Novel Delivery System for Subcutaneous and Orthotopic Colon Cancer Therapy
por: Pan C, et al.
Publicado: (2021) -
RECEPTOR SUPERFAMILY OF TUMOR NECROSIS FACTOR Α, AND HSP90 HEAT SHOCK PROTEIN: A MOLECULAR BASIS FOR INTERACTIONS
por: N. V. Ryazantseva, et al.
Publicado: (2014) -
Plasmatic Levels of HSP90α at Diagnosis: A Novel Prognostic Indicator of Clinical Outcome in Advanced Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors Plus Chemotherapy
por: Shubin Chen, et al.
Publicado: (2021)